Clinicopathological and molecular analysis of endometrioid carcinoma based on the expressions of ER, PgR and HER2

2015 Fiscal Year Final Research Report

• Project/Area Number: 25460420
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Human pathology
• Research Institution: Iwate Medical University
• Principal Investigator: Sugai Tamotsu 岩手医科大学, 医学部, 教授 (20187628)
• Co-Investigator(Renkei-kenkyūsha): Sugiyama Tooru 岩手医科大学, 医学部, 教授 (40162903)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: 類内膜腺癌 / 遺伝子変異 / KRAS / p53 / PIK3CA / メチル化 / LOH

Outline of Final Research Achievements

The aim of this study was to examine molecular alterations in endometrial cancer (EA) based on the expression of these biomarkers. Samples from 83 EAs were obtained. We classified EAs based on expression of ER, PgR, and HER2. Microsatellite instability (MSI), DNA methylation status, loss of heterozygosity (LOH) and mutations in oncogenes were examined. Types were defined as follows: Type A (ER+ and/or PgR+, HER2-), Type B (ER+ and/or PgR+, HER2+), Type C (ER/PgR-, HER2+), and Type D (ER/PgR-, HER2-). The frequency of PTEN expression in Type C was lower than that in other types. Ki-ras mutations were more frequent in Type C, and PIK3CA mutations were more common in Types A and B. The frequency of LOH-high status in Type C and D was significantly higher than that in Types A and B. Subtypes based on these biomarkers in EA were characterized by each different molecular abnormality.

Free Research Field

腫瘍病理学、消化器病理学、病理診断学